Spectranetics Enrolls First Patients in Myocardial Infarction Trial
Posted on: Friday, 6 June 2008, 09:01 CDT
Spectranetics has announced enrollment of the first patients in the thromboablation in acute myocardial infarction, or Taami, trial. The Taami trial is a planned 200-patient randomized trial involving major medical centers in Poland.
Starting last quarter, Taami enrolled its first six patients and recently initiated the fifth participating hospital.
The trial comprises two treatment groups and enrolls the most complex acute myocardial infarction (AMI) patients - those with a large thrombus burden presenting with ST wave elevation myocardial infarction.
The study group receives excimer laser treatment plus direct stenting. The control group receives balloon angioplasty and stenting. The primary endpoint is a combination of ST resolution, which is resolution of the electrocardiogram ST wave elevation injury pattern and the amount of distal embolization as measured by myocardial blush scores.
John Schulte, president and CEO of Spectranetics, said: "The Taami trial represents an important new opportunity for Spectranetics to evaluate the performance of the excimer laser in these acute myocardial infarction patients."
Source: Datamonitor
Related Articles
- D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
- D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
- Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)
- Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients With Acute Myelogenous Leukemia
- Alexza Completes Enrollment in AZ-004 Phase IIa Clinical Trial in Schizophrenic Patients With Acute Agitation
- Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients With Acute Myeloid Leukemia
- RenaMed Biologics Reports Positive Phase II Data With Renal Bio-Replacement Therapy; Phase II Study Results Show Improved Survival Rates in Patients With Acute Renal Failure
- CVBT Announces It Will Begin U.S. FDA-Authorized Clinical Trials in Diabetic Patients With Open Wounds
- Effect of Pamidronate Administration on Bone in Patients With Acute Spinal Cord Injury
- Reports Show Correlations of Genasense(R) Levels With Target and Biomarker Effects in Patients With Acute Myelocytic Leukemia and Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds